Exact Sciences (EXAS) closed the most recent trading day at $60.68, moving -0.49% from the previous trading session. This change was narrower than the S&P 500’s daily loss of 2.77%. Meanwhile, the Dow lost 2.82%, and the Nasdaq, a tech-heavy index, lost 0.83%.
Heading into today, shares of the molecular diagnostics company had lost 9.13% over the past month, lagging the Medical sector’s loss of 0.16% and the S&P 500’s loss of 1.35% in that time.
Investors will be hoping for strength from Exact Sciences as it approaches its next earnings release, which is expected to be April 26, 2022. In that report, analysts expect Exact Sciences to post earnings of -$1.12 per share. This would mark a year-over-year decline of 522.22%. Our most recent consensus estimate is calling for quarterly revenue of $461.86 million, up 14.87% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.33 per share and revenue of $2.01 billion. These totals would mark changes of -24.43% and +13.68%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Exact Sciences. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company’s business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Exact Sciences is holding a Zacks Rank of #3 (Hold) right now.
The Medical – Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EXAS in the coming trading sessions, be sure to utilize Zacks.com.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
